- Report
- January 2025
- 132 Pages
Global
From €865EUR$950USD£734GBP
- Report
- November 2021
- 86 Pages
Global
€4323EUR$4,750USD£3,672GBP
- Report
- July 2024
- 280 Pages
Global
From €1692EUR$1,859USD£1,437GBP
€2416EUR$2,655USD£2,052GBP
- Report
- April 2022
- 220 Pages
Global
From €2202EUR$2,419USD£1,870GBP
€3146EUR$3,456USD£2,672GBP
- Report
- March 2022
- 172 Pages
Global
From €2365EUR$2,598USD£2,009GBP
€3379EUR$3,712USD£2,870GBP
- Report
- February 2022
- 172 Pages
Global
From €2365EUR$2,598USD£2,009GBP
€3379EUR$3,712USD£2,870GBP
- Book
- May 2021
- 640 Pages
- Book
- July 2020
- 464 Pages
- Book
- May 2019
- 1304 Pages
- Book
- October 2010
- 408 Pages
- Book
- August 2010
- 480 Pages
- Book
- January 2010
- 200 Pages
- Book
- January 2009
- 448 Pages

Cardiac Resynchronization (CRT) is a type of cardiovascular device used to treat heart failure. It is a therapy that uses electrical stimulation to synchronize the contractions of the left and right ventricles of the heart. This helps to improve the heart's pumping efficiency and reduce symptoms of heart failure. CRT is typically used in combination with other treatments such as medications, lifestyle changes, and implantable cardioverter-defibrillators (ICDs).
CRT devices are typically implanted in the chest and consist of a pulse generator, leads, and electrodes. The pulse generator sends electrical signals to the heart through the leads and electrodes, which are connected to the left and right ventricles. The electrical signals help to coordinate the contractions of the ventricles, improving the heart's pumping efficiency.
CRT is a rapidly growing market, with a wide range of products available from various manufacturers. Companies in the market include Medtronic, Abbott, Boston Scientific, Biotronik, and St. Jude Medical. Show Less Read more